Panmure Gordon reaffirmed their under review rating on shares of Dechra Pharmaceuticals plc (LON:DPH) in a research report released on Tuesday morning.
Several other research firms also recently weighed in on DPH. N+1 Singer lifted their target price on shares of Dechra Pharmaceuticals plc from GBX 1,350 ($16.29) to GBX 1,412 ($17.03) and gave the stock a buy rating in a research report on Friday, October 21st. Stifel Nicolaus reissued a hold rating and issued a GBX 1,250 ($15.08) target price on shares of Dechra Pharmaceuticals plc in a research report on Friday, October 21st. Numis Securities Ltd reissued an add rating and issued a GBX 1,520 ($18.34) target price on shares of Dechra Pharmaceuticals plc in a research report on Thursday, October 27th. FinnCap restated an under review rating on shares of Dechra Pharmaceuticals plc in a report on Tuesday, November 29th. Finally, Jefferies Group raised their price target on shares of Dechra Pharmaceuticals plc from GBX 1,295 ($15.62) to GBX 1,320 ($15.92) and gave the stock a hold rating in a report on Thursday, December 15th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Dechra Pharmaceuticals plc currently has an average rating of Buy and a consensus price target of GBX 1,337.43 ($16.13).
Shares of Dechra Pharmaceuticals plc (LON:DPH) opened at 1430.08 on Tuesday. The firm’s market cap is GBX 1.33 billion. The stock has a 50 day moving average of GBX 1,325.03 and a 200 day moving average of GBX 1,322.15. Dechra Pharmaceuticals plc has a 52-week low of GBX 811.00 and a 52-week high of GBX 1,462.00.
In other Dechra Pharmaceuticals plc news, insider Tony Griffin sold 17,133 shares of Dechra Pharmaceuticals plc stock in a transaction that occurred on Wednesday, November 30th. The shares were sold at an average price of GBX 1,292 ($15.59), for a total value of £221,358.36 ($267,050.74).
Dechra Pharmaceuticals plc Company Profile
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.